Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Phase 2 Multi-Center Study of SM-88 in Patients with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy

Clinical Trial Details

This is a phase 2 clinical trial for men and women with pancreatic cancer, whose disease has progressed or recurred after/on first line chemotherapy. The objective of this study is to obtain data of overall survival and overall response rate in the subject population. 

Approximately 53,070 people develop exocrine pancreatic cancer each year in the United States. Exocrine pancreatic cancer typically has an aggressive growth profile and late-stage presentation of symptoms. Eighty percent of patients that are diagnosed with this cancer usually have a morality of one-year with few effective treatment alternatives. Surgical resection offers the best chance of cure. However, only 9 percent of subjects are diagnosed at the localized stage, causing the majority of pancreatic cancer cases to be unresectable. 

Current available treatment are only effective in small numbers of patients. Thus, there is a need for more effective, less toxic anti-cancer agents. 

Key Eligibility: 
  • Men and women age 18 and older
  • Diagnosis of pancreatic cancer 
  • Have failed at least one line of prior systemic therapy
  • Detailed eligibility reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan

Contact(s)

Carina Puello, RN
(646) 962-3541
cap4008@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1803019092

ClinicalTrials.gov:

NCT03512756

Sponsor:

Tyme-88-Panc

Status

Open to Enrollment

Age Group

Adult

Sponsor